| [1] |
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018,68(6):394-424. DOI: 10.3322/caac.21492.
doi:10.3322/caac.21492pmid:30207593 |
| [2] |
Chen HM, Feng G. Use of anlotinib in intra-abdominal desmoplastic small round cell tumors: a case report and literature review[J]. Onco Targets Ther, 2018,12:57-61. DOI: 10.2147/OTT.S190333.
doi:10.2147/OTT.S190333pmid:30588030 |
| [3] |
Xie C, Wan X, Quan H, et al. Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor[J]. Cancer Sci, 2018,109(4):1207-1219. DOI: 10.1111/cas.13536.
doi:10.1111/cas.13536pmid:29446853 |
| [4] |
Sun Y, Du F, Gao M, et al. Anlotinib for the treatment of patients with locally advanced or metastatic medullary thyroid cancer[J]. Thyroid, 2018,28(11):1455-1461. DOI: 10.1089/thy.2018.0022.
doi:10.1089/thy.2018.0022pmid:30142994 |
| [5] |
Chi Y, Fang Z, Hong X, et al. Safety and efficacy of anlotinib, a multikinase mngiogenesis inhibitor, in patients with refractory metastatic soft-tissue sarcoma[J]. Clin Cancer Res, 2018,24(21):5233-5238. DOI: 10.1158/1078-0432.CCR-17-3766.
doi:10.1158/1078-0432.CCR-17-3766pmid:29895706 |
| [6] |
Sun Y, Niu W, Du F, et al. Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors[J]. J Hematol Oncol, 2016,9(1):105. DOI: 10.1186/s13045-016-0332-8.
doi:10.1186/s13045-016-0332-8pmid:27716285 |
| [7] |
Wang G, Sun M, Jiang Y, et al. Anlotinib, a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcoma[J]. Int J Cancer, 2019,145(4):979-993. DOI: 10.1002/ijc.32180.
doi:10.1002/ijc.32180pmid:30719715 |
| [8] |
Wang L, He Z, Yang S, et al. The impact of previous therapy stra-tegy on the efficiency of anlotinib hydrochloride as a third-line treatment on patients with advanced non-small cell lung cancer (NSCLC): a subgroup analysis of ALTER0303 trial[J]. Transl Lung Cancer Res, 2019,8(5):575-583. DOI: 10.21037/tlcr.2019.09.21.
doi:10.21037/tlcr.2019.09.21pmid:31737494 |
